Feasibility and effectiveness of cotrimoxazole prophylaxis for HIV-1-infected adults attending an HIV/AIDS clinic in Uganda

Journal of Acquired Immune Deficiency Syndromes

Volumn 42, Issue 3, 2006, Pages 373-378

  Watera, Christine ^a   Todd, Jim ^b   Muwonge, Richard ^a   Whitworth, James ^a,b   Nakiyingi Miiro, Jessica ^a   Brink, Anne ^a   Miiro, George ^a   Antvelink, Lucy ^c   Kamali, Anatoli ^a   French, Neil ^d   Mermin, Jonathan ^a  

^a UGANDA VIRUS RESEARCH INSTITUTE   (Uganda)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c AIDS Support Organisation ^*  (Uganda)

^d LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

Author keywords

Africa; Epidemiology; HIV AIDS mortality; Microbical drug resistance; Morbidity; Opportunistic infections

Indexed keywords

COTRIMOXAZOLE;

ADULT; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEVELOPING COUNTRY; DRUG EFFICACY; DRUG ERUPTION; FEASIBILITY STUDY; FEMALE; HEALTH CENTER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALARIA; MALE; MORBIDITY; MORTALITY; OPPORTUNISTIC INFECTION; PATIENT COMPLIANCE; PRIORITY JOURNAL; PRURITUS; UGANDA;

ADOLESCENT; ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-INFECTIVE AGENTS; CD4 LYMPHOCYTE COUNT; FEASIBILITY STUDIES; HIV INFECTIONS; HUMANS; TREATMENT OUTCOME; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION; UGANDA;

EID: 33745926803     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qai.0000221679.14445.1b     Document Type: Article

References (19)

1. UNAIDS. Better prospects for preventing infections in those with HIV. Report on the Global HIV/AIDS Epidemic. June 2000;105-106. Available at: http://data.unaids.org/Global-Reports/Durban/Durban_ Epi_report_en.pdf. Accessed November 2005.
2. Anglaret X, Chene G, Attia A, et al. Early chemoprophylaxis with trirnethoprim-sulphamethoxazole for HIV-1-infected adults in Abidjan, Cote d'Ivoire. A randomised trial. Lancet. 1999;353:1463-1468.
3. Wiktor SZ, Sassan-Morokro M, Grant AD, et al. Efficacy of trimethoprim-sulphamethoxazole prophylaxis to decrease morbidity and mortality in HIV-1-infected patients with tuberculosis in Abidjan, Cote d'Ivoire: a randomised controlled trial. Lancet. 1999;353:1469-1475.
4. Badri M, Ehrlich R, Wood R, et al. Initiating cotrimoxazole prophylaxis in HIV-infected patients in Africa: an evaluation of the provisional WHO/UNAIDS recommendations. AIDS. 2001;15:1143-1148.
5. Zachariah R, Spielmann M-P, Chinji C, et al. Voluntary counselling, HIV testing and adjunctive cotrimoxazole reduces mortality in tuberculosis patients in Thyolo, Malawi. AIDS. 2003;17:1053-1061.
6. Mermin J, Lule J, Ekwaru JP, et al. Effect of cotrimoxazole prophylaxis on morbidity, mortality, CD4 cell count, and viral load in HIV infection in rural Uganda. Lancet. 2004;364:1428-1434.
7. Grimwade K, Sturm AW, Nunn AJ, et al. Effectiveness of cotrimoxazole prophylaxis on mortality in adults with tuberculosis in rural South Africa. AIDS. 2005;19:163-168.
8. Maynart M, Lievre L, Sow PS, et al. Primary prevention with cotrimoxazole for HIV-1-infected adults: results of the pilot study in Dakar, Senegal. J Acquir Immune Defic Syndr. 2001;26:130-136.
9. Mwaungulu FBD, Floyd S, Crampin AC, et al. Cotrimoxazole prophylaxis reduces mortality in human immunodeficiency virus-positive tuberculosis patients in Karonga district, Malawi. Bull World Health Organ. 2004;82:354-363.
10. Boeree MJ, Sauvageot D, Banda HT, et al. Efficacy and safety of two dosages of cotrimoxazole as preventive treatment for HIV-infected Malawian adults with new smear-positive tuberculosis. Trop Med Int Health. 2005;10:723-733.
11. Kariuki S, Gilks C, Corkhill J, et al. Multi-drug resistant non-typhi Salmonella in Kenya. J Antimicrob Chemother. 1996;38:425-434.
12. Iyer JK, Milhous WK, Cortese JF, et al. Plasmodium falciparum cross resistance between trimethoprim and pyrimethamine. Lancet. 2001;358:1066-1067.
13. Kilian AHD, Jelinek T, Prislin I, et al. Resistance in vivo of Plasmodium falciparum to cotrimoxazole in western Uganda. Trans R Soc Trop Med Hyg. 1998;92:197-200.
14. Thera MA, Sehdev PS, Coulibaly D, et al. Impact of trimethoprim- sulfamethoxazole prophylaxis on falciparum malaria infection and disease. JID. 2005;192:1823-1829.
15. Grimwade K, Gilks C. Cotrimoxazole prophylaxis in adults infected with HIV in low-income countries. Curr Opin Infect Dis. 2001;14:507-512.
16. Ministry of Health, Republic of Uganda. National policy guidelines for cotrimoxazole prophylaxis for people with HIV/AIDS. April 2005.
17. French N, Nakiyingi J, Carpenter LM, et al. 23-Valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial. Lancet. 2000;355:2106-2111.
18. The WHO International Collaborating Group for the Study of the WHO Staging System. Proposed "World Health Organisation staging system for HIV infection and disease": preliminary testing by an international collaborative cross-sectional study. AIDS. 1993;7:711-718.
19. Mermin J, Lule JR, Ekwaru JP. Association between malaria and CD4 cell count decline among persons with HIV. JAIDS. 2006;41(1):129-130.